Acutus Completes $170M Financing To Support AcQMap Commercialization
The deal includes $100m in Series D financing and a $70m credit facility to help Acutus market the AcQMap electrophysiology mapping system along with the associated vascular access devices, AcQCross QX, AcQGuide Flex and AcQGuide Mini.
You may also be interested in...
The IPO is expected to raise $166m to support R&D of new arrhythmia mapping and ablation technologies and expand commercial operations.
Acutus Medical Inks Marketing Deal With Biotronik, Mapping Its Way To Electrophysiologists Outside US
Biotronik will help Acutus to bring its cardiac mapping software and guidance system to electrophysiologists worldwide.
Device financing totaled $2.3bn for Q2 2019, with the debt category bringing in the most money. Merger and acquisition deals reached an aggregate $9.1bn (a 25% increase from Q1), thanks mostly to 3M’s $6.7bn takeover of Acelity and its KCI subsidiaries. Diagnostics/research financing, which totaled $2.4bn, showed a significant rise from the previous quarter, while diagnostics/research tools M&A values, at $233m, exhibited a steep decline.